MedCity News March 24, 2024
The “holy grail” of ATMP-based treatments is to provide cures for some of the world’s most debilitating disease states, but for this to occur, a unified front is needed to democratize these therapies – collaboration from industry, academia, supply chain and, indeed, clinicians and hospitals is paramount to ensuring safe manufacturing and transit.
In laboratories around the globe, scientists are diligently researching the limitless potential of advanced therapeutic medicinal products (ATMPs). These groundbreaking therapies are changing the face of healthcare by harnessing the potential of the human body for healing. Using cells, proteins, antibodies, tissues and nucleic acids as “living” therapies is simultaneously promising, but also brings unique challenges from a manufacturing, supply chain, and patient treatment standpoint. The advent...
Today's Sponsors
Today's Sponsor